Affluent Medical SAS
Affluent Medical SA, a medical technology company, develops and markets minimally invasive minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardio… Read more
Affluent Medical SAS (AFME) - Net Assets
Latest net assets as of June 2025: €21.11 Million EUR
Based on the latest financial reports, Affluent Medical SAS (AFME) has net assets worth €21.11 Million EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€59.84 Million) and total liabilities (€38.73 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €21.11 Million |
| % of Total Assets | 35.28% |
| Annual Growth Rate | -7.98% |
| 5-Year Change | -14.22% |
| 10-Year Change | N/A |
| Growth Volatility | 22.47 |
Affluent Medical SAS - Net Assets Trend (2016–2024)
This chart illustrates how Affluent Medical SAS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Affluent Medical SAS (2016–2024)
The table below shows the annual net assets of Affluent Medical SAS from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €30.27 Million | -3.82% |
| 2023-12-31 | €31.47 Million | -6.98% |
| 2022-12-31 | €33.83 Million | -22.29% |
| 2021-12-31 | €43.53 Million | +23.36% |
| 2020-12-31 | €35.29 Million | +13.97% |
| 2019-12-31 | €30.96 Million | -49.57% |
| 2017-12-31 | €61.39 Million | +4.29% |
| 2016-12-31 | €58.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Affluent Medical SAS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6898700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €3.94 Million | 13.00% |
| Other Comprehensive Income | €-70.76 Million | -233.77% |
| Other Components | €167.95 Million | 554.83% |
| Total Equity | €30.27 Million | 100.00% |
Affluent Medical SAS Competitors by Market Cap
The table below lists competitors of Affluent Medical SAS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VISIOMED GROUP EO 001
F:7V91
|
$31.65 Million |
|
EnviroGold Global Limited
OTCQB:ESGLF
|
$31.65 Million |
|
Sea Oil Public Company Limited
BK:SEAOIL
|
$31.65 Million |
|
Loulis Mills S.A.
AT:KYLO
|
$31.66 Million |
|
9M00
F:9M00
|
$31.64 Million |
|
AfriTin Mining Limited
PINK:AFTTF
|
$31.63 Million |
|
Precipio Inc
NASDAQ:PRPO
|
$31.61 Million |
|
Maxiparts Ltd
AU:MXI
|
$31.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Affluent Medical SAS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 31,472,000 to 30,271,000, a change of -1,201,000 (-3.8%).
- Net loss of 14,739,000 reduced equity.
- Share repurchases of 12,722,000 reduced equity.
- New share issuances of 12,722,000 increased equity.
- Other comprehensive income decreased equity by 13,094,000.
- Other factors increased equity by 26,632,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-14.74 Million | -48.69% |
| Share Repurchases | €12.72 Million | -42.03% |
| Share Issuances | €12.72 Million | +42.03% |
| Other Comprehensive Income | €-13.09 Million | -43.26% |
| Other Changes | €26.63 Million | +87.98% |
| Total Change | €- | -3.82% |
Book Value vs Market Value Analysis
This analysis compares Affluent Medical SAS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.65x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.58x to 3.65x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | €4.83 | €2.81 | x |
| 2017-12-31 | €5.04 | €2.81 | x |
| 2019-12-31 | €1.67 | €2.81 | x |
| 2020-12-31 | €1.90 | €2.81 | x |
| 2021-12-31 | €2.34 | €2.81 | x |
| 2022-12-31 | €1.79 | €2.81 | x |
| 2023-12-31 | €1.08 | €2.81 | x |
| 2024-12-31 | €0.77 | €2.81 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Affluent Medical SAS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -48.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -357.92%
- • Asset Turnover: 0.07x
- • Equity Multiplier: 2.01x
- Recent ROE (-48.69%) is below the historical average (-36.97%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -9.92% | -194566.67% | 0.00x | 1.05x | €-11.72 Million |
| 2017 | -14.26% | -20353.49% | 0.00x | 1.10x | €-14.89 Million |
| 2019 | -53.58% | -1160.88% | 0.02x | 2.11x | €-19.69 Million |
| 2020 | -40.58% | -1737.74% | 0.01x | 1.84x | €-17.85 Million |
| 2021 | -34.04% | -1021.36% | 0.02x | 1.61x | €-19.17 Million |
| 2022 | -45.01% | -1137.19% | 0.02x | 1.77x | €-18.61 Million |
| 2023 | -49.74% | -1278.84% | 0.02x | 1.80x | €-18.80 Million |
| 2024 | -48.69% | -357.92% | 0.07x | 2.01x | €-17.77 Million |
Industry Comparison
This section compares Affluent Medical SAS's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $33,413,879
- Average return on equity (ROE) among peers: -31.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Affluent Medical SAS (AFME) | €21.11 Million | -9.92% | 1.83x | $31.64 Million |
| Biosynex (ALBIO) | $124.31 Million | -29.72% | 0.94x | $7.06 Million |
| Bluelinea SA (ALBLU) | $1.96 Million | -41.72% | 0.71x | $6.02 Million |
| Carmat (ALCAR) | $-43.76 Million | 0.00% | 0.00x | $3.28 Million |
| Diagnostic Medical Systems SA (ALDMS) | $13.72 Million | -36.04% | 2.73x | $13.39 Million |
| Eurobio Scientific SA (ALERS) | $175.17 Million | 2.76% | 0.81x | $5.52 Million |
| Ikonisys SA (ALIKO) | $20.01 Million | -2.85% | 0.13x | $9.76 Million |
| Implanet SA (ALIMP) | $3.54 Million | -99.97% | 3.09x | $6.96 Million |
| Mediantechn (ALMDT) | $0.00 | 0.00% | 0.00x | $86.92 Million |
| Spineguard (ALSGD) | $5.77 Million | -78.70% | 0.48x | $5.70 Million |